FORM
6-K
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
For
the Month of June, 2024
Commission
File Number 0-51504
GENETIC
TECHNOLOGIES LIMITED
(Exact
Name as Specified in its Charter)
N/A
(Translation
of Registrant’s Name)
60-66
Hanover Street
Fitzroy
Victoria
3065 Australia
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statement
on Form F-3 (File Nos. 333-276168), to be a part thereof
from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
June 5, 2024
| GENETIC
TECHNOLOGIES LIMITED |
|
| |
|
| By: |
/s/
Kathryn Andrews |
|
| Name: |
Kathryn
Andrews |
|
| Title: |
Company
Secretary |
|
Exhibit
99.1
ASX
Market Announcement
|
 |
GeneType
and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test
Melbourne,
Australia, June 5, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global
leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology,
are excited to announce a major distribution agreement. This partnership will bring GTG’s innovative Multi-Risk Test to
a broader audience in the online pharmacy channel across North America, empowering individuals to take control of their health.
Stayhealthy
is at the forefront of integrating technology with health solutions. The company’s mission is to empower, inspire, and give hope
to individuals, families, and communities through enhanced technology and a global wellness network. Their FDA-cleared technologies have
enabled users to measure, track, and improve their health significantly.
In
2023, Stayhealthy launched an online discount pharmacy with 1.5 million users and a Level 5 cafeteria workers insurance plan1,2
covering over 100,000 employees. With a database of over 200 million U.S. email addresses, Stayhealthy is well-positioned to promote
this new offering.
John
Collins, previously successful in the music industry and public relations, was inspired to transform healthcare after a personal experience.
His extensive industry connections have been instrumental in Stayhealthy’s growth.
GeneType
will now distribute the Multi-Risk Test via StayHealthyRx, enhancing the reach of its portfolio of personalized health risk assessments
across North America. This collaboration will provide users with comprehensive insights into their health risks and actionable steps
to mitigate them.
“Partnering
with GeneType allows us to reach more people with Gene Types Multi-Risk Test, offering a powerful tool for health management,”
said John Collins, CEO of Stayhealthy. “Genetype’s expertise in non-invasive genetic testing complements our technology perfectly.”
Genetic
Technologies CEO, Simon Morriss “We are excited to partner with Stayhealthy and bring the innovative Multi-Risk Test to their customers,
this test will help individuals make informed health decisions and improve their quality of life.”
For
more information, please visit Stayhealthy and GeneType.
-
END -
Authorised
for release by the Board of Directors.
1
https://www.business.com/articles/benefits-of-section-125-plan/#what-is-a-section-125-plan
2
https://www.openpr.com/news/3487694/level-five-health-partners-with-stayhealthy-to-empower-users
Enquiries
Simon
Morriss
Chief
Executive Officer
E:
investors@genetype.com
About
Genetic Technologies Limited
Genetic
Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests
in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment
tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform
that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and
individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues
to develop risk assessment products. For more information, please visit www.genetype.com
Forward
Looking Statements
This
announcement may contain forward-looking statements about the Company’s expectations, beliefs or intentions regarding, among other
things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made
or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as “believe,” “expect,” “intend,” “plan,” “may,” “should”
or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not
limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made
by or with the approval of one of the Company’s authorized executive officers. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual
results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause
the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings with the
ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities
values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any
obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by law.
Genetic Technologies (NASDAQ:GENE)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Genetic Technologies (NASDAQ:GENE)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
